Veoza (fezolinetant) has been officially approved for use on the NHS to prevent hot flushes in menopausal women, marking a significant advancement in treatment options. This new drug is expected to benefit around 500,000 women in England, particularly those for whom hormone replacement therapy (HRT) is unsuitable.

Impact of Hot Flushes

Hot flushes affect approximately 70% of women experiencing menopause, leading to considerable discomfort and disruption in daily life. Helen Knight, a representative from NICE, stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” This highlights the urgent need for effective treatments.

How Veoza Works

Veoza is designed as a once-daily oral tablet that operates by blocking nerve pathways in the brain responsible for triggering hot flushes and night sweats. This mechanism offers a new approach to managing symptoms that have long been challenging for many women.

Cost and Accessibility

The NHS list price for Veoza is set at £44.80 per 28-tablet pack, which NICE has deemed cost-effective and valuable for taxpayers. This approval is particularly significant given the historical lack of safe and effective treatment options for menopausal symptoms.

Expert Opinions

Dr. Sue Mann expressed optimism about the approval, stating, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She added that Veoza represents another vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.

Future Expectations

With the approval of Veoza, healthcare professionals and patients alike are hopeful for improved quality of life for those suffering from menopausal symptoms. The introduction of this treatment is expected to provide much-needed relief, especially for women who have struggled with inadequate options in the past.

As the healthcare community prepares for the rollout of Veoza, details remain unconfirmed regarding its availability and distribution across the NHS. Nevertheless, the approval of this drug marks a pivotal moment in the ongoing conversation about women’s health and menopause management.

The post Veoza Approved for Menopause Treatment in England appeared first on News Casino.

Veoza (fezolinetant) has received approval for use on the NHS in England, marking a significant advancement in the treatment of menopausal hot flushes. This new oral medication is aimed at the approximately 500,000 women in England who experience these symptoms and for whom hormone replacement therapy (HRT) is unsuitable.

Hot flushes are a common symptom affecting around 70% of women undergoing menopause, often leading to discomfort and a diminished quality of life. Veoza is designed to alleviate these symptoms by blocking nerve pathways in the brain that trigger hot flushes and night sweats, offering a once-daily oral tablet as a treatment option.

The NHS has set the list price for Veoza at £44.80 for a 28-tablet pack. The National Institute for Health and Care Excellence (NICE) has evaluated fezolinetant and deemed it cost-effective, providing value for taxpayers while addressing a pressing health need.

Helen Knight from NICE emphasized the importance of this treatment, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added that this decision will provide much-needed relief to women who cannot or choose not to take HRT.

Dr. Sue Mann, a prominent figure in women’s health, remarked, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She further noted that Veoza represents a vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.

For decades, treatment options for menopausal hot flushes have been limited, with many women seeking alternatives to HRT. The introduction of Veoza is expected to change this landscape, providing a new avenue for symptom management.

As the rollout of Veoza begins, healthcare providers and patients alike are optimistic about its potential impact on women’s health. However, details remain unconfirmed regarding the full extent of its availability and distribution across the NHS.

The post Veoza: New Approval for Menopause Treatment in England appeared first on News Casino.